Table 1.
Aortic, clinical, biochemical, and bone characteristics of the 66 patients with ESRDa
| Variable | Active Bone(n = 33) | Adynamic Bone(n = 33) | P |
|---|---|---|---|
| AoCS (mean ± SEM) | 3.60 ± 0.80 | 12.00 ± 1.10 | <0.0001 |
| Aortic PWV (m/s; mean ± SEM) | 9.43 ± 0.35 | 12.52 ± 0.38 | <0.0001 |
| Age (yr; mean ± SEM) | 43.00 ± 2.60 | 53.60 ± 1.60 | <0.0010 |
| Gender (male/female) | 16/17 | 17/16 | NS |
| Smoking (pack-years; median [95% CI]) | 5.00 (0.00 to 16.00) | 3.50 (0.00 to 9.00) | NS |
| Vintage (mo; mean ± SEM) | 80.00 ± 8.50 | 90.00 ± 11.40 | NS |
| SBP (mmHg; mean ± SEM) | 154.00 ± 4.20 | 158.50 ± 3.60 | NS |
| DBP (mmHg; mean ± SEM) | 85.60 ± 2.40 | 84.20 ± 2.30 | NS |
| Antihypertensive drugs (no/yes) | 11/22 | 11/22 | NS |
| Total cholesterol (mmol/L; mean ± SEM) | 5.07 ± 0.25 | 5.21 ± 0.18 | NS |
| Serum albumin (g/L; mean ± SEM) | 39.7 ± 0.40 | 37.5 ± 0.40 | <0.0010 |
| CRP (mg/L; median [95% CI]) | 3.00 (2.00 to 5.00) | 9.00 (7.00 to 11.00) | <0.0010 |
| Serum Ca (mmol/L; mean ± SEM) | 2.43 ± 0.03 | 2.43 ± 0.03 | NS |
| Ionized Ca (mmol/L; mean ± SEM) | 1.23 ± 0.01 | 1.20 ± 0.01 | NS |
| Serum PO4 (mmol/L; mean ± SEM) | 1.92 ± 0.06 | 2.03 ± 0.07 | NS |
| Ca*PO4 (mmol2/L2; mean ± SEM) | 4.67 ± 0.15 | 4.95 ± 0.19 | NS |
| PTH (pg/ml; median [95% CI]) | 420.00 (327.00 to 549.00) | 142.00 (57.00 to 570.00) | <0.0001 |
| Serum Al (μmol/L; mean ± SEM) | 1.28 ± 0.14 | 1.60 ± 0.17 | NS |
| Deferoxamine test (ΔAl μmol/L; mean ± SEM) | 2.03 ± 0.28 | 2.60 ± 0.28 | NS |
| CaCO3 (g elemental Ca/d; mean ± SEM) | 1.47 ± 0.20 | 1.97 ± 0.14 | 0.0200 |
| 1α-OH-D3 (μg/d; median [95% CI]) | 0.25 (0.00 to 0.25) | 0.00 (0.00 to 0.25) | NS |
| Resorption surfaces (%; median [95% CI]) | 2.83 (2.18 to 3.47) | 0.19 (0.00 to 0.50) | <0.0001 |
| Osteoclasts/mm2; (median [95% CI]) | 2.14 (1.31 to 2.69) | 0.18 (0.09 to 0.40) | <0.0001 |
| Osteoblastic surfaces (%; median [95% CI]) | 13.20 (10.50 to 15.00) | 1.17 (0.42 to 2.12) | <0.0001 |
| Double tetracycline–labeled surfaces (%; median [95% CI]) | 13.50 (8.00 to 16.0) | 0.00 (0.00 to 0.00) | <0.0001 |
| Trabecular volume (%; median [95% CI]) | 21.2 (15.3 to 23.8) | 19.5 (15.4 to 29.1) | NS |
| Osteoid surface (%; median [95% CI]) | 53.5 (44.0 to 64.0) | 43.5 (33.0 to 58.0) | NS |
| Al-stained surfaces (%; median [95% CI]) | 6.0 (0.0 to 23.0) | 46.0 (17.0 to 75.0) | <0.0100 |
| Post-PTX hypoparathyroidism (yes/no) | 0/33 | 8/25 | 0.0020 |
| Glomerulonephritis (n) | 15 | 11 | NS |
| CPNPh, interstitial nephritis (n) | 11 | 10 | NS |
| Polycystic kidney disease (n) | 3 | 8 | NS |
| Nephroangiosclerosis (n) | 3 | 2 | NS |
| Diabetes (n) | 1 | 2 | NS |
a
Reference values: Resorption surfaces (%): 0.4 ± 0.3; osteoclasts/mm2: 0.15 ± 0.05; osteoblastic surfaces (%): 4 ± 2; trabecular volume (%): 15 to 22; osteoid surface (%): 15 ± 5. CI, confidence interval; CPNPh, chronic pyelonephritis; CRP, C-reactive protein; DBP, diastolic BP; SBP, systolic BP.